Filtered By:
Source: Lancet Neurology
Management: National Institutes of Health (NIH)
Therapy: Stem Cell Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
In Context News in brief
The Pilot Investigation of Stem Cells in Stroke (PISCES) phase 1, first-in-man study assessed the safety of single intracerebral doses of CTX-DP —a drug derived from the immortalised human neural stem-cell line, CTX0E03. This open-label, single-site, dose-escalation study recruited 13 men aged 60 years and older with stable disability (National Institutes of Health Stroke Scale [NIHSS] score ≥6 and modified Rankin Scale score of 2–4) f ollowing ischaemic stroke 6–60 months before enrolment. 11 men received implantation of single doses of 2 million, 5 million, 10 million, or 20 million cells by stereotactic ipsilate...
Source: Lancet Neurology - September 13, 2016 Category: Neurology Tags: In Context Source Type: research
